Comparison of risk factor reduction and tolerability of a full-dose polypill (With Potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases: The second indian polycap study (TIPS-2) investigators

Circulation: Cardiovascular Quality and Outcomes

Volumn 5, Issue 4, 2012, Pages 463-471

  Yusuf, Salim ^a   Pais, Prem ^b   Sigamani, Alben ^b   Xavier, Denis ^b   Afzal, Rizwan ^a   Gao, Peggy ^a   Teo, Koon K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

Blood pressure; Cardiovascular disease; Lipids; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; RAMIPRIL; SIMVASTATIN; SODIUM; TRIACYLGLYCEROL;

ADULT; ARTICLE; ASTHMA; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG CAPSULE; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPEPSIA; FATIGUE; GASTRITIS; HEART RATE; HIGH RISK POPULATION; HUMAN; HYPOTENSION; INDIA; INTENTION TO TREAT ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MICROALBUMINURIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUPPLEMENTATION; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VERTIGO; WEAKNESS;

ADMINISTRATION, ORAL; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; ASPIRIN; ATENOLOL; BIOLOGICAL MARKERS; BLOOD PRESSURE; CAPSULES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CREATININE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEART RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDIA; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYPHARMACY; POTASSIUM; RAMIPRIL; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864624301     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.111.963637     Document Type: Article

References (18)

1. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81-106.
2. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
3. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol; a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
5. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2-3.
6. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
7. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen M, Probstfield J, Fodor G, Held C, Genest Jr, J, The Heart Outcomes Prevention Evaluation (HOPE) Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1-11.
8. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078-2088.
9. The Indian Polycap Study (TIPS), Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet. 2009;373:1341-1351.
10. PILL Collaborative Group. An international randomized placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One. 2011;6:e19857.
11. O'Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, McQueen M, Sleight P, Sharma AM, Dans A, Probstfield J, Schmieder RE. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306:2229-2238.
12. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373:1849-1860.
13. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-1237.
14. Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ; ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364:928-938.
15. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.
16. Feng J, He G, MacGregor A. Beneficial effects of potassium. BMJ. 2001;323:497-501.
17. Berry SE, Mulla UZ, Chowienczyk PJ, Sanders TA. Increased potassium intake from fruit and vegetables or supplements does not lower blood pressure or improve vascular function in UK men and women with early hypertension: a randomised controlled trial. Br J Nutr. 2010;104:1839-1847.
18. Bulpitt CJ, Ferrier G, Lewis PJ, Daymond M, Bulpitt PF, Dollery CT. Potassium supplementation fails to lower blood pressure in hypertensive patients receiving a potassium losing diuretic. Ann Clin Res. 1985;17:126-130.